101
Participants
Start Date
June 7, 2017
Primary Completion Date
December 24, 2024
Study Completion Date
December 24, 2024
Dolutegravir film-coated tablets
Dolutegravir film-coated tablets will be provided as 50 mg tablets.
Dolutegravir film-coated dispersible tablets
Dolutegravir film-coated dispersible tablets will be provided as 5 mg dispersible tablets. It will be administered at the appropriate dose as determined by results of the parent protocol to participants as per their age and weight band.
ABC/DTG/3TC immediate release tablets
ABC/DTG/3TC immediate release tablets will be provided as biconvex, oval tablets containing 600 mg ABC, 50 mg DTG and 300 mg 3TC.
ABC/DTG/3TC film-coated dispersible tablets
ABC/DTG/3TC dispersible tablets will be provided as biconvex, oval, film-coated tablets containing 60 mg ABC, 5 mg DTG and 30 mg 3TC.
GSK Investigational Site, Soweto
GSK Investigational Site, Johannesburg
GSK Investigational Site, Moshi
GSK Investigational Site, Umlazi
GSK Investigational Site, Cape Town
GSK Investigational Site, Bangkok
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Chiang Mai
GSK Investigational Site, Chiang Rai
GSK Investigational Site, Los Angeles
GSK Investigational Site, Memphis
GSK Investigational Site, Gaborone
GSK Investigational Site, Harare
GSK Investigational Site, Belo Horizonte
GSK Investigational Site, Nova Iguaçu
GSK Investigational Site, RibeirAo PretoSP
GSK Investigational Site, Rio de Janeiro
Lead Sponsor
ViiV Healthcare
INDUSTRY